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CHAPAS-3 ﬁ lls the gap
While the eﬃ  cacy of protease inhibitors versus non-
nucleoside reverse transcriptase inhibitors for ﬁ rst-line 
paediatric antiretroviral treatment (ART) has been 
carefully assessed in clinical trials, only one small trial 
(PENTA-5)1 has compared diﬀ erent nucleoside reverse 
transcriptase inhibitor (NRTIs) backbones in children. The 
PENTA-5 trial noted that abacavir-containing regimens 
were more eﬀ ective than zidovudine plus  lamivudine, 
but was done in resource-rich settings and the regimen 
included nelﬁ navir in nearly half of participants, restricting 
its relevance to current treatment decision in Africa, where 
most paediatric HIV infections occur. Consequently, to 
inform its recommendations on the optimum dual 
NRTI backbone for paediatric ART, the WHO has relied 
on data from randomised trials without head-to-head 
comparisons of NRTIs, observational cohort data, and 
expert opinion. The near complete absence of trial data 
in children is unacceptable in the context of lifelong ART, 
which requires a good understanding of the eﬀ ect of 
diﬀ erent NRTI backbones on toxicity, achievement and 
maintenance of viral suppression, and implications of 
mutations on future treatment options. The CHAPAS-3 
trial2 now ﬁ lls this gap by providing the ﬁ rst trial data 
comparing abacavir, stavudine, and zidovudine in 
combination with lamivudine and nevirapine or efavirenz 
for ﬁ rst-line treatment in HIV-positive children in Africa.
In 2013, the WHO recommended abacavir plus 
lamivudine as the preferred dual NRTI backbone in 
children because “abacavir can be used once daily, 
is available as a ﬁ xed-dose combination with 3TC 
[[lamivudine], and harmonises with TDF [tenofovir]
from a resistance perspective”.3 This change occurred 
despite the relatively high cost of abacavir and the 
association of abacavir with hypersensitivity reactions.4 
Furthermore, observational data from two cohort 
studies indicated that abacavir might be less eﬀ ective in 
achieving and maintaining viral suppression compared 
with similar regimens containing stavudine, raising 
concerns among clinicians and policy makers about the 
WHO recommendation.5,6 
In the multicentre CHAPAS-3 trial,2 478 children 
age 1 month to 13 years were randomly assigned 
to receive ﬁ xed-dose combination tablets of one 
of three NRTIs (abacavir, stavudine, or zidovudine) 
plus lamivudine in combination with nevirapine or 
efavirenz, all dosed according to WHO weight bands. 
The trial included 365 ART-naive children and 113 
virologically suppressed ART-experienced children on 
a stavudine-containing ﬁ rst-line regimen for 2 years 
or more. The study achieved superb completion rates 
with only 5% of children lost to follow-up and 98% of 
scheduled nurse visits completed. Clinical outcomes 
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were excellent for all three NRTIs, with low (4%) 
mortality, high (≥80%) viral load suppression rates in 
ART-naive children, high (>96%) maintenance of viral 
suppression at 48 weeks in ART-experienced children, 
and no evidence of diﬀ erential CD4% recovery across 
randomised groups. 
In children with ongoing viral replication, sensitivity 
to second-line drugs remained high independent of the 
NRTI used. Toxicity was low and independent of NRTI 
group, with no diﬀ erences noted in the proportion of 
children with grade 2 or more clinical or grade 3 or more 
laboratory adverse events (67% in stavudine group, 65% 
in zidovudine group, and 64% in abacavir group; p=0·63) 
with grade 2 respiratory tract infections accounting for 
more than half of all primary endpoints. Few children (4% 
who received stavudine, 8% who received zidovudine, and 
3% who received abacavir) presented with grade 3 or more 
adverse events with possible relations to NRTIs, and only 
6% of children changed regimens during the 2·3 years of 
median follow-up. Of note, a higher proportion of children 
in the zidovudine group then in the other two treatment 
groups had their ART regimen modiﬁ ed as a result of 
toxicity, even though there was no evidence that grade 3 or 
4 anaemia was more frequent in that group. This ﬁ nding 
potentially indicates a lower threshold among clinicians 
to modifying therapy in children receiving zidovudine. 
The endpoint review committee diagnosed nine children 
with a hypersensitivity reaction: ﬁ ve in the stavudine 
group, one child on zidovudine, and two receiving abacavir 
(p=0·21). Both children receiving abacavir continued the 
drug without adverse consequences, a ﬁ nding that shows 
the diﬃ  culty in making an accurate clinical diagnosis of 
abacavir hypersensitivity. 
In conclusion, the CHAPAS-3 trial2 refutes the 
concerns of reduced eﬃ  cacy of abacavir-containing 
NRTI backbone for ﬁ rst-line ART that was raised by 
observational studies, and strongly suggests that NRTI 
backbone with efavirenz or nevirapine in children 
is associated with very low toxicities and high viral 
load suppression rates independent of the NRTI used. 
These data are reassuring and support clinicians 
and policy makers in their implementation of the 
current WHO guidelines, which recommend abacavir 
plus lamivudine as the preferred NRTI backbone for 
paediatric ART. 
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Artemisinin-based combination therapy for knowlesi malaria
For decades, human Plasmodium knowlesi infections were 
misclassiﬁ ed as other forms of human malaria because of 
their morphological similarities seen during microscopic 
assessment.1 This misclassiﬁ cation became evident only 
with the availability of molecular diagnostic techniques. 
Since then, results of intensive research have shown that 
P knowlesi infection can progress rapidly to severe disease in 
the human host as a result of its 24 h asexual reproduction 
cycle, that P knowlesi is the most prevalent human malaria 
species in Malaysia, and that other countries in southeast 
Asia also harbour substantial numbers of human cases 
of this simian malaria parasite.2,3 Importantly, there is 
no evidence for a direct transmission cycle between 
human beings and the anopheline vector; monkeys are 
the necessary intermediate host sustaining ongoing 
transmission of this zoonotic Plasmodium species.3
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